Skip to main content

Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021.

Publication ,  Journal Article
Tenforde, MW; Self, WH; Naioti, EA; Ginde, AA; Douin, DJ; Olson, SM; Talbot, HK; Casey, JD; Mohr, NM; Zepeski, A; Gaglani, M; McNeal, T ...
Published in: MMWR Morb Mortal Wkly Rep
August 27, 2021

Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated hospitalizations (1-4) measured shortly after vaccination; longer follow-up is needed to assess durability of protection. In an evaluation at 21 hospitals in 18 states, the duration of mRNA vaccine (Pfizer-BioNTech or Moderna) effectiveness (VE) against COVID-19-associated hospitalizations was assessed among adults aged ≥18 years. Among 3,089 hospitalized adults (including 1,194 COVID-19 case-patients and 1,895 non-COVID-19 control-patients), the median age was 59 years, 48.7% were female, and 21.1% had an immunocompromising condition. Overall, 141 (11.8%) case-patients and 988 (52.1%) controls were fully vaccinated (defined as receipt of the second dose of Pfizer-BioNTech or Moderna mRNA COVID-19 vaccines ≥14 days before illness onset), with a median interval of 65 days (range = 14-166 days) after receipt of second dose. VE against COVID-19-associated hospitalization during the full surveillance period was 86% (95% confidence interval [CI] = 82%-88%) overall and 90% (95% CI = 87%-92%) among adults without immunocompromising conditions. VE against COVID-19- associated hospitalization was 86% (95% CI = 82%-90%) 2-12 weeks and 84% (95% CI = 77%-90%) 13-24 weeks from receipt of the second vaccine dose, with no significant change between these periods (p = 0.854). Whole genome sequencing of 454 case-patient specimens found that 242 (53.3%) belonged to the B.1.1.7 (Alpha) lineage and 74 (16.3%) to the B.1.617.2 (Delta) lineage. Effectiveness of mRNA vaccines against COVID-19-associated hospitalization was sustained over a 24-week period, including among groups at higher risk for severe COVID-19; ongoing monitoring is needed as new SARS-CoV-2 variants emerge. To reduce their risk for hospitalization, all eligible persons should be offered COVID-19 vaccination.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

MMWR Morb Mortal Wkly Rep

DOI

EISSN

1545-861X

Publication Date

August 27, 2021

Volume

70

Issue

34

Start / End Page

1156 / 1162

Location

United States

Related Subject Headings

  • mRNA Vaccines
  • Young Adult
  • Vaccines, Synthetic
  • Vaccination
  • United States
  • Time Factors
  • Middle Aged
  • Male
  • Humans
  • Hospitalization
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tenforde, M. W., Self, W. H., Naioti, E. A., Ginde, A. A., Douin, D. J., Olson, S. M., … IVY Network, . (2021). Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep, 70(34), 1156–1162. https://doi.org/10.15585/mmwr.mm7034e2
Tenforde, Mark W., Wesley H. Self, Eric A. Naioti, Adit A. Ginde, David J. Douin, Samantha M. Olson, H Keipp Talbot, et al. “Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021.MMWR Morb Mortal Wkly Rep 70, no. 34 (August 27, 2021): 1156–62. https://doi.org/10.15585/mmwr.mm7034e2.
Tenforde MW, Self WH, Naioti EA, Ginde AA, Douin DJ, Olson SM, et al. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1156–62.
Tenforde, Mark W., et al. “Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021.MMWR Morb Mortal Wkly Rep, vol. 70, no. 34, Aug. 2021, pp. 1156–62. Pubmed, doi:10.15585/mmwr.mm7034e2.
Tenforde MW, Self WH, Naioti EA, Ginde AA, Douin DJ, Olson SM, Talbot HK, Casey JD, Mohr NM, Zepeski A, Gaglani M, McNeal T, Ghamande S, Shapiro NI, Gibbs KW, Files DC, Hager DN, Shehu A, Prekker ME, Erickson HL, Gong MN, Mohamed A, Henning DJ, Steingrub JS, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Hough CL, Busse LW, Ten Lohuis CC, Duggal A, Wilson JG, Gordon AJ, Qadir N, Chang SY, Mallow C, Rivas C, Babcock HM, Kwon JH, Exline MC, Halasa N, Chappell JD, Lauring AS, Grijalva CG, Rice TW, Jones ID, Stubblefield WB, Baughman A, Womack KN, Lindsell CJ, Hart KW, Zhu Y, Stephenson M, Schrag SJ, Kobayashi M, Verani JR, Patel MM, IVY Network Investigators, IVY Network. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1156–1162.

Published In

MMWR Morb Mortal Wkly Rep

DOI

EISSN

1545-861X

Publication Date

August 27, 2021

Volume

70

Issue

34

Start / End Page

1156 / 1162

Location

United States

Related Subject Headings

  • mRNA Vaccines
  • Young Adult
  • Vaccines, Synthetic
  • Vaccination
  • United States
  • Time Factors
  • Middle Aged
  • Male
  • Humans
  • Hospitalization